Clinical Trials
5 trialsNCT03602859 2025-12-31
FIRST
Tesaro, Inc.
Phase 3 Active not recruiting
NCT05201547 2025-12-04
DOMENICA
ARCAGY/ GINECO GROUP
Phase 3 Active not recruiting
NCT04655976 2025-09-26
COSTAR Lung
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06472076 2025-09-10
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03981796 2025-09-03
RUBY
Tesaro, Inc.
Phase 3 Active not recruiting